Skip to main content
Erschienen in: Heart Failure Reviews 3/2013

01.05.2013

Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion

verfasst von: Konstantinos Karatolios, Sabine Pankuweit, Bernhard Maisch

Erschienen in: Heart Failure Reviews | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to examine the biochemical composition of pericardial effusions of different etiology and to evaluate the diagnostic utility of biochemical parameters and tumor markers to discriminate malignant from benign effusion. Pericardial and serum levels of biochemical parameters and tumor markers were compared in 105 patients who underwent pericardiocentesis and pericardioscopy with targeted epicardial biopsy. Etiologic diagnosis was based on pericardial fluid and epicardial biopsy analysis by cytology, histology, immunohistochemistry, microbiology and polymerase chain reaction. The total of 105 patients comprised 29 patients with malignant and 76 patients with non-malignant pericardial effusions (40 autoreactive, 28 viral, 5 postcardiotomy syndromes and 3 associated with systemic diseases). Malignant pericardial effusions had significantly higher pericardial fluid levels of the tumor markers CEA, CA 19-9, CA 72-4, SCC and NSE (p < 0.001, p = 0.002, p < 0.001, p = 0.004 and p < 0.001, respectively) as well as higher pericardial fluid hemoglobin (p < 0.001), pericardial fluid white blood cells (p = 0.003), pericardial fluid LDH (p < 0.001) and ratio of pericardial to serum LDH levels compared to benign effusions. None of the biochemical or cell-count parameters tested proved to be accurate enough for distinguishing malignant from benign effusions. However, measurement of pericardial CA 72-4 levels offered a high diagnostic accuracy for malignancy, particularly in bloody pericardial effusions. None of the biochemical parameters tested was useful for the discrimination of malignant from benign effusions. However, measurement of pericardial CA 72-4 levels in bloody pericardial effusions yielded a high diagnostic accuracy and thus offers the potential as a diagnostic tool to distinguish between malignant and benign effusions.
Literatur
2.
Zurück zum Zitat Maisch B, Ristic AD (2003) Practical aspects of the management of pericardial disease. Heart 89(9):1096–1103PubMedCrossRef Maisch B, Ristic AD (2003) Practical aspects of the management of pericardial disease. Heart 89(9):1096–1103PubMedCrossRef
3.
Zurück zum Zitat Maisch B, Ristic AD, Pankuweit S, Neubauer A, Moll R (2002) Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 23(20):1625–1631PubMedCrossRef Maisch B, Ristic AD, Pankuweit S, Neubauer A, Moll R (2002) Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 23(20):1625–1631PubMedCrossRef
5.
Zurück zum Zitat Sagrista-Sauleda J, Merce J, Permanyer-Miralda G, Soler–Soler J (2000) Clinical clues to the causes of large pericardial effusions. Am J Med 109(2):95–101PubMedCrossRef Sagrista-Sauleda J, Merce J, Permanyer-Miralda G, Soler–Soler J (2000) Clinical clues to the causes of large pericardial effusions. Am J Med 109(2):95–101PubMedCrossRef
7.
Zurück zum Zitat Meyers DG, Meyers RE, Prendergast TW (1997) The usefulness of diagnostic tests on pericardial fluid. Chest 111(5):1213–1221PubMedCrossRef Meyers DG, Meyers RE, Prendergast TW (1997) The usefulness of diagnostic tests on pericardial fluid. Chest 111(5):1213–1221PubMedCrossRef
8.
Zurück zum Zitat Corey GR, Campbell PT, Van Trigt P, Kenney RT, O‘Connor CM, Sheikh KH, Kisslo JA, Wall TC (1993) Etiology of large pericardial effusions. Am J Med 95(2):209–213PubMedCrossRef Corey GR, Campbell PT, Van Trigt P, Kenney RT, O‘Connor CM, Sheikh KH, Kisslo JA, Wall TC (1993) Etiology of large pericardial effusions. Am J Med 95(2):209–213PubMedCrossRef
10.
Zurück zum Zitat Maisch B, Bethge C, Drude L, Hufnagel G, Herzum M, Schonian U (1994) Pericardioscopy and epicardial biopsy—new diagnostic tools in pericardial and perimyocardial disease. Eur Heart J 15(Suppl C):68–73PubMedCrossRef Maisch B, Bethge C, Drude L, Hufnagel G, Herzum M, Schonian U (1994) Pericardioscopy and epicardial biopsy—new diagnostic tools in pericardial and perimyocardial disease. Eur Heart J 15(Suppl C):68–73PubMedCrossRef
11.
Zurück zum Zitat Seferovic PM, Ristic AD, Maksimovic R, Tatic V, Ostojic M, Kanjuh V (2003) Diagnostic value of pericardial biopsy: improvement with extensive sampling enabled by pericardioscopy. Circulation 107(7):978–983PubMedCrossRef Seferovic PM, Ristic AD, Maksimovic R, Tatic V, Ostojic M, Kanjuh V (2003) Diagnostic value of pericardial biopsy: improvement with extensive sampling enabled by pericardioscopy. Circulation 107(7):978–983PubMedCrossRef
12.
Zurück zum Zitat Porte HL, Janecki-Delebecq TJ, Finzi L, Metois DG, Millaire A, Wurtz AJ (1999) Pericardoscopy for primary management of pericardial effusion in cancer patients. Eur J Cardiothorac Surg 16(3):287–291PubMedCrossRef Porte HL, Janecki-Delebecq TJ, Finzi L, Metois DG, Millaire A, Wurtz AJ (1999) Pericardoscopy for primary management of pericardial effusion in cancer patients. Eur J Cardiothorac Surg 16(3):287–291PubMedCrossRef
13.
Zurück zum Zitat Burgess LJ, Reuter H, Taljaard JJ, Doubell AF (2002) Role of biochemical tests in the diagnosis of large pericardial effusions. Chest 121(2):495–499PubMedCrossRef Burgess LJ, Reuter H, Taljaard JJ, Doubell AF (2002) Role of biochemical tests in the diagnosis of large pericardial effusions. Chest 121(2):495–499PubMedCrossRef
15.
Zurück zum Zitat Gold P, Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439–462PubMedCrossRef Gold P, Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439–462PubMedCrossRef
16.
Zurück zum Zitat Goldstein MJ, Mitchell EP (2005) Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23(4):338–351PubMedCrossRef Goldstein MJ, Mitchell EP (2005) Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23(4):338–351PubMedCrossRef
17.
Zurück zum Zitat Gold P, Shuster J, Freedman SO (1978) Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections. Cancer 42(3 Suppl):1399–1405PubMedCrossRef Gold P, Shuster J, Freedman SO (1978) Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections. Cancer 42(3 Suppl):1399–1405PubMedCrossRef
18.
Zurück zum Zitat Cutait R, Alves VA, Lopes LC, Cutait DE, Borges JL, Singer J, da Silva JH, Goffi FS (1991) Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 34(10):917–920PubMedCrossRef Cutait R, Alves VA, Lopes LC, Cutait DE, Borges JL, Singer J, da Silva JH, Goffi FS (1991) Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 34(10):917–920PubMedCrossRef
19.
Zurück zum Zitat Kato H, Torigoe T (1977) Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40(4):1621–1628PubMedCrossRef Kato H, Torigoe T (1977) Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40(4):1621–1628PubMedCrossRef
20.
Zurück zum Zitat Suminami Y, Nawata S, Kato H (1998) Biological role of SCC antigen. Tumour Biol 19(6):488–493PubMedCrossRef Suminami Y, Nawata S, Kato H (1998) Biological role of SCC antigen. Tumour Biol 19(6):488–493PubMedCrossRef
21.
Zurück zum Zitat Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito MR, Greiner JW et al (1995) CA 72-4 serum marker–a new tool in the management of carcinoma patients. Cancer Invest 13(2):227–238PubMedCrossRef Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito MR, Greiner JW et al (1995) CA 72-4 serum marker–a new tool in the management of carcinoma patients. Cancer Invest 13(2):227–238PubMedCrossRef
22.
Zurück zum Zitat Filella X, Molina R, Jo J, Bedini JL, Joseph J, Ballesta AM (1992) Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. Bull Cancer 79(3):271–277PubMed Filella X, Molina R, Jo J, Bedini JL, Joseph J, Ballesta AM (1992) Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. Bull Cancer 79(3):271–277PubMed
23.
Zurück zum Zitat Aloe S, D’Alessandro R, Spila A, Ferroni P, Basili S, Palmirotta R, Carlini M, Graziano F, Mancini R, Mariotti S, Cosimelli M, Roselli M, Guadagni F (2003) Prognostic value of serum and tumor tissue CA 72-4 content in gastric cancer. Int J Biol Markers 18(1):21–27PubMed Aloe S, D’Alessandro R, Spila A, Ferroni P, Basili S, Palmirotta R, Carlini M, Graziano F, Mancini R, Mariotti S, Cosimelli M, Roselli M, Guadagni F (2003) Prognostic value of serum and tumor tissue CA 72-4 content in gastric cancer. Int J Biol Markers 18(1):21–27PubMed
24.
Zurück zum Zitat Louhimo J, Alfthan H, Stenman UH, Haglund C (2004) Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 66(2):126–131. doi:10.1159/000077438 PubMedCrossRef Louhimo J, Alfthan H, Stenman UH, Haglund C (2004) Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 66(2):126–131. doi:10.​1159/​000077438 PubMedCrossRef
25.
Zurück zum Zitat Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C (2002) Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 101(6):545–548. doi:10.1002/ijc.90009 PubMedCrossRef Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C (2002) Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 101(6):545–548. doi:10.​1002/​ijc.​90009 PubMedCrossRef
27.
Zurück zum Zitat Parra JL, Kaplan S, Barkin JS (2005) Elevated CA 19-9 caused by Hashimoto’s thyroiditis: review of the benign causes of increased CA 19-9 level. Dig Dis Sci 50(4):694–695PubMedCrossRef Parra JL, Kaplan S, Barkin JS (2005) Elevated CA 19-9 caused by Hashimoto’s thyroiditis: review of the benign causes of increased CA 19-9 level. Dig Dis Sci 50(4):694–695PubMedCrossRef
28.
Zurück zum Zitat Cooper EH, Splinter TA, Brown DA, Muers MF, Peake MD, Pearson SL (1985) Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer. Br J Cancer 52(3):333–338PubMedCrossRef Cooper EH, Splinter TA, Brown DA, Muers MF, Peake MD, Pearson SL (1985) Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer. Br J Cancer 52(3):333–338PubMedCrossRef
29.
Zurück zum Zitat Gronowitz JS, Bergstrom R, Nou E, Pahlman S, Brodin O, Nilsson S, Kallander CF (1990) Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 66(4):722–732PubMedCrossRef Gronowitz JS, Bergstrom R, Nou E, Pahlman S, Brodin O, Nilsson S, Kallander CF (1990) Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 66(4):722–732PubMedCrossRef
30.
Zurück zum Zitat Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R, Kuzmits R (1990) Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer 65(6):1386–1390PubMedCrossRef Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R, Kuzmits R (1990) Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer 65(6):1386–1390PubMedCrossRef
31.
Zurück zum Zitat Maisch B, Ristic AD, Pankuweit S (2002) Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J 23(19):1503–1508PubMedCrossRef Maisch B, Ristic AD, Pankuweit S (2002) Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J 23(19):1503–1508PubMedCrossRef
32.
Zurück zum Zitat Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmuller R, Adler Y, Tomkowski WZ, Thiene G, Yacoub MH (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 25(7):587–610PubMedCrossRef Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmuller R, Adler Y, Tomkowski WZ, Thiene G, Yacoub MH (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 25(7):587–610PubMedCrossRef
33.
Zurück zum Zitat Szturmowicz M, Tomkowski W, Fijalkowska A, Kupis W, Cieslik A, Demkow U, Langfort R, Wiechecka A, Orlowski T, Torbicki A (2005) Diagnostic utility of CYFRA 21-1 and CEA assays in pericardial fluid for the recognition of neoplastic pericarditis. Int J Biol Markers 20(1):43–49PubMed Szturmowicz M, Tomkowski W, Fijalkowska A, Kupis W, Cieslik A, Demkow U, Langfort R, Wiechecka A, Orlowski T, Torbicki A (2005) Diagnostic utility of CYFRA 21-1 and CEA assays in pericardial fluid for the recognition of neoplastic pericarditis. Int J Biol Markers 20(1):43–49PubMed
34.
Zurück zum Zitat Karatolios K, Pankuweit S, Goettsch C, Hofbauer LC, Timmesfeld N, Al-Fakhri N, Maisch B, Schoppet M (2012) Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. Clin Biochem 45(3):237–242. doi:10.1016/j.clinbiochem.2011.12.003 PubMedCrossRef Karatolios K, Pankuweit S, Goettsch C, Hofbauer LC, Timmesfeld N, Al-Fakhri N, Maisch B, Schoppet M (2012) Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. Clin Biochem 45(3):237–242. doi:10.​1016/​j.​clinbiochem.​2011.​12.​003 PubMedCrossRef
35.
Zurück zum Zitat Maisch BRA, Seferovic PM, Tsang TSM (2012) Interventional pericardiology: pericardiocentesis, pericardioscopy, pericardial biopsy, balloon pericardiotomy, and intrapericardial therapy. Springer, Heidelberg Maisch BRA, Seferovic PM, Tsang TSM (2012) Interventional pericardiology: pericardiocentesis, pericardioscopy, pericardial biopsy, balloon pericardiotomy, and intrapericardial therapy. Springer, Heidelberg
36.
Zurück zum Zitat Maisch B, Ristic AD, Seferovic PM, Spodick DH (2000) Intrapericardial treatment of autoreactive myocarditis with triamcinolon. Successful administration in patients with minimal pericardial effusion. Herz 25(8):781–786PubMedCrossRef Maisch B, Ristic AD, Seferovic PM, Spodick DH (2000) Intrapericardial treatment of autoreactive myocarditis with triamcinolon. Successful administration in patients with minimal pericardial effusion. Herz 25(8):781–786PubMedCrossRef
Metadaten
Titel
Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion
verfasst von
Konstantinos Karatolios
Sabine Pankuweit
Bernhard Maisch
Publikationsdatum
01.05.2013
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 3/2013
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-012-9327-x

Weitere Artikel der Ausgabe 3/2013

Heart Failure Reviews 3/2013 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.